WHWK — Whitehawk Therapeutics Cashflow Statement
0.000.00%
- $130.07m
- -$32.52m
- $25.98m
- 57
- 30
- 63
- 49
Annual cashflow statement for Whitehawk Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.32 | -110 | -60.5 | -65.8 | -63.7 |
| Depreciation | |||||
| Non-Cash Items | 1.35 | 75.3 | 12.5 | 9.34 | 10 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.48 | 12.2 | -1.82 | -3.4 | -6.05 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -5.38 | -22.4 | -49.6 | -59.7 | -59.5 |
| Capital Expenditures | -0.019 | -0.046 | -0.444 | -3.97 | -1.65 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 25.2 | -132 | 87.2 | 26.9 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.019 | 25.2 | -133 | 83.2 | 25.2 |
| Financing Cash Flow Items | -0.403 | -9.62 | -0.659 | -0.16 | -0.016 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 9.48 | 142 | 72.6 | 0.326 | 0.13 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.08 | 145 | -110 | 23.9 | -34.2 |